Boston-based Heranova Lifesciences, a women’s health care company focused on reproductive health, pregnancy and menopause, announced the launch with $13.5 million in seed and seed+ financing.
Emerging technology partners, pivotal bioVenture Partners China, Sinovation Ventures and Triwise Capital participated in the round.
WHAT IT DOES
The company, which also has a presence in China, offers diagnostic tests and therapies for endometriosis and a non-antibiotic vaginal bacteria medicine for bacterial vaginosis. It also offers a genetic test, an endometrial receptivity test, and a microbiome trio test for female fertility.
Heranova will use the funds to launch several non-invasive endometriosis tests and continue two therapeutic programs for bacterial vaginosis and endometriosis.
“Having access to convenient and reliable diagnostic tests will be an important milestone in the overall treatment of endometriosis and other women’s diseases,” said Dr. Farideh Bischoff, head of medical diagnostics at Heranova, said in a statement.
“The diagnostic products developed by our R&D team have received the support of world-leading KOLs as they can help significantly reduce the time from disease onset to diagnosis and subsequent treatment. integrated solution, we are also developing first-in-class, non-hormonal therapeutic programs for endometriosis.”
MARKET SNAPSHOT
Women’s health technology continues to form a relatively small part of total digital health funding, and the sector is too ripe for investment.
Other companies focused on digital healthcare innovations that have secured funding include virtual healthcare providers for women and families Maven Clinicwhich went up $90 million in Series E funding last year, bringing its total revenue to $300 million.
Maternity-focused digital healthcare company Diana Health secured $34 million in Series B funding in October, hybrid fertility and reproductive care company Friendliness scored $25 million in May, and women’s healthcare platform Iron Healththat allows obstetrician-gynecologists to connect their patients to primary and other specialty care, launched in March with $4.5 million in seed funding.